arrow
A

Akiko Chiba

Duke University
H指数:21
被引数:1,523

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ASO Visual Abstract: Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery

ASO视觉摘要:ER阳性、HER2阴性乳腺癌腋窝手术的当代趋势,根据新辅助内分泌治疗、新辅助化疗或初始手术进行分层。

2025-12-040
PRE
ASO Visual Abstract: Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the Covid-19 Pandemic

ASO视觉摘要:雌激素受体阳性乳腺癌的新辅助内分泌治疗应用:来自新冠疫情期间实践转变的见解

2025-10-150
PRE
Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery

当代腋窝手术趋势:基于新辅助内分泌治疗、新辅助化疗或直接手术的ER阳性、HER2阴性乳腺癌分层研究

2025-09-230
OAAI
ASO Visual Abstract: Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

ASO可视化摘要:新辅助化疗与改善转移性乳腺癌的总体生存率无关,无论肿瘤亚型如何。

2025-08-260
PRE
Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype

新辅助化疗与肿瘤亚型无关,对化生性乳腺癌的总生存期无改善作用。

2025-07-290
PRE
Risk Stratification for Sentinel Lymph Node Positivity in Older Women With Early-Stage Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Neu-Negative Invasive Breast Cancer
2025-03-010
PRE